Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer.
Epidermal growth factor receptor (EGFR) is a target in head and neck cancer. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. The aim of this study is to determine if clinical biological correlates are more accurate when different aspects of EGFR are evaluated in combination. We analyzed the EGFR phosphorylation, expression, and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage but also discovered two novel EGFR truncations.
Keller
James
J
Division of Pediatric Hematology/Oncology, Stony Brook University, Stony Brook, New York 11794-8111, USA.
Shroyer
Kenneth R
KR
Batajoo
Shishir K
SK
Zhao
Hong-Ling
HL
Dong
Li Ming
LM
Hayman
Michael J
MJ
Chan
Edward L
EL
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D010766:Phosphorylation; D020133:Reverse Transcriptase Polymerase Chain Reaction
C512478:EGFR protein, human; D066246:ErbB Receptors